KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Depreciation & Amortization - TotalEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Non-Controlling InterestsInterest ExpensesNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

National Health Investors (NHI) EBITDA (2016 - 2022)

National Health Investors (NHI) has disclosed EBITDA for 14 consecutive years, with $8.2 million as the latest value for Q1 2022.

  • For the quarter ending Q1 2022, EBITDA fell 77.81% year-over-year to $8.2 million, compared with a TTM value of $132.2 million through Mar 2022, down 33.16%, and an annual FY2021 reading of $8.2 million, down 77.81% over the prior year.
  • EBITDA was $8.2 million for Q1 2022 at National Health Investors, down from $41.0 million in the prior quarter.
  • Across five years, EBITDA topped out at $62.4 million in Q3 2019 and bottomed at $8.2 million in Q1 2022.
  • Average EBITDA over 5 years is $41.5 million, with a median of $40.4 million recorded in 2018.
  • The sharpest move saw EBITDA soared 50.81% in 2020, then tumbled 77.81% in 2022.
  • Year by year, EBITDA stood at $59.1 million in 2018, then increased by 5.61% to $62.4 million in 2019, then decreased by 26.63% to $45.8 million in 2020, then decreased by 10.58% to $41.0 million in 2021, then plummeted by 79.88% to $8.2 million in 2022.
  • Business Quant data shows EBITDA for NHI at $8.2 million in Q1 2022, $41.0 million in Q2 2021, and $37.2 million in Q1 2021.